Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis

Pediatric Rheumatology

Volumn 13, Issue 1, 2015, Pages

  Kostik, Mikhail M ^a   Dubko, Margarita F ^a   Masalova, Vera V ^a   Snegireva, Ludmila S ^a   Kornishina, Tatyana L ^a   Chikova, Irina A ^a   Isupova, Eugenia A ^a   Kuchinskaya, Ekaterina M ^a   Glebova, Natalia I ^a   Buchinskaya, Natalia V ^a   Kalashnikova, Olga V ^a   Chasnyk, Vyacheslav G ^a  

^a SAINT PETERSBURG STATE PEDIATRIC MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Biologic free remission; High disease activity; Interleukine 6; Low disease activity; Systemic onset juvenile idiopathic arthritis; Tocilizumab

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HEMOGLOBIN; IMMUNOGLOBULIN G; INTERLEUKIN 6; LACTATE DEHYDROGENASE; METHOTREXATE; PROTEIN; TOCILIZUMAB; MONOCLONAL ANTIBODY;

ACROCYANOSIS; ALBUMIN BLOOD LEVEL; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILL; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GRANULOCYTE; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HEPATOMEGALY; HUMAN; HYPOTENSION; INFUSION RELATED REACTION; INTERSTITIAL LUNG DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LYMPHADENOPATHY; MACROPHAGE ACTIVATION SYNDROME; MALE; PALLOR; PHYSICIAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; SPLENOMEGALY; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, JUVENILE; COHORT ANALYSIS; COMPARATIVE STUDY; DOSE RESPONSE; IMMUNOLOGY; ONSET AGE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

AGE OF ONSET; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, JUVENILE; CHILD; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERLEUKIN-6; MALE; METHOTREXATE; REMISSION, SPONTANEOUS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924209085     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-13-4     Document Type: Article

References (26)

1. Martini A: Systemic juvenile idiopathic arthritis. Autoimmun Rev 2012, 12:56-9. 10.1016/j.autrev.2012.07.022
2. Gurion R, Lehman TJ, Moorthy LN: Systemic arthritis in children: a review of clinical presentation and treatment. Int J Inflam 2012, 2012:271569.
3. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al.: Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367:2396-406. 10.1056/NEJMoa1205099
4. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al.: Therapeutic efficacy of humanized recombinant anti-interleukin6receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005, 52:818-25. 10.1002/art.20944
5. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al.: Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371:998-1006. 10.1016/S0140-6736(08)60454-7
6. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al.: Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367:2385-95. 10.1056/NEJMoa1112802
7. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J: Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1blockade. J Exp Med 2005, 201:1479-86. 10.1084/jem.20050473
8. De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A: Correlation of serum interleukin-6 with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991, 34:1158-63. 10.1002/art.1780340912
9. De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A: Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994, 93:2114-9. 10.1172/JCI117206
10. De Benedetti F: Tocilizumab for systemic juvenile idiopathic arthritis. N Engl J Med 2013, 368:1256-7.
11. Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, et al.: Open label phase II trial of single, ascending doses of MRA in Caucasianchildren with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005, 7:R1281-8. 10.1186/ar1826
12. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, et al.: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006, 54:2817-29. 10.1002/art.22033
13. Brunner HI, Ruperto N, Zuber Z, Cuttica RJ, Xavier R, Calvo I, et al.: Efficacy and Safety Of Tocilizumab In Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-YearData From Cherish. Arthritis Rheum 2013, 65:S335.
14. Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, et al.: Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol 2012, 22:109-15. 10.3109/s10165-011-0481-0
15. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al.: International League ofAssociations for Rheumatology. International League of Associations for Rheumatologyclassification of juvenile idiopathic arthritis: second revision, Edmonton 2001. J Rheumatol 2004, 31:390-2.
16. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A: Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997, 40:1202-9. 10.1002/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R
17. Ravelli A: Macrophage activation syndrome. Curr Opin Rheumatol 2002, 14:548-52. 10.1097/00002281-200209000-00012
18. Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al.: Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005, 146:598-604. 10.1016/j.jpeds.2004.12.016
19. Wallace CA, Ruperto N, Giannini E: Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. J Rheumatol 2004, 31:2290-4.
20. Woo P: Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat ClinPract Rheumatol 2006, 2:28-34. 10.1038/ncprheum0084
21. DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al.: Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Juvenile Idiopathic Arthritis Disease-specific Research Committee of Childhood Arthritis Rheumatology and Research Alliance. Arthritis Care Res (Hoboken) 2012, 64:1001-10.
22. Gattorno M, Piccini A, Lasigliè D, Tassi S, Brisca G, Carta S, et al.: The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008, 58:1505-15. 10.1002/art.23437
23. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al.: Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989, 74:1360-7.
24. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al.: Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005, 106:2627-32. 10.1182/blood-2004-12-4602
25. De Benedetti F, Pignatti P, Gerloni V, Massa M, Sartirana P, Caporali R, et al.: Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol 1997, 24:1403-9.
26. Kessler EA, Vora SS, Verbsky JW: Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome. Pediatr Rheumatol Online J 2012, 10:30. 10.1186/1546-0096-10-30